Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH, describes the FDA approval of brentuximab vedotin in combination with chemotherapy for patients with previously untreated peripheral T-cell lymphomas (PTCL). Approval was based on results from the Phase II ECHELON-2 trial (NCT01777152) of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in CD30+ mature T-cell lymphomas. Dr Jagadeesh discusses data presented at the ASH 2020 meeting which showed continued benefit with brentuximab vedotin plus CHOP. The SGN35-032 trial (NCT04569032) will explore brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (A+CHP) for patients with previously untreated PTCL with under 10% CD30 expression. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.